Corbus Pharmaceuticals Holdings Inc

NASDAQ:CRBPUnited States

Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio. The Company's pipeline is comprised of two experimental drugs targeting solid tumors: CRB-701, which is an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, which is an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells. Its pipeline also includes CRB-913, which is a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has in-licensed the intellectual property for CRB-601 from Dr. Stephen Nishimura's laboratory at the University of California, San Francisco. The Company does not own or operate manufacturing facilities and relies on third-party contract manufacturing organizations or licensing partners to supply it with drugs for pre-clinical and clinical studies and commercial activities.

Contact Information

Headquarters

500 River Ridge DriveNORWOOD, MA, United States 02062

Phone

617-963-0103

Fax

---

Executives

Independent Director

Alan Holmer

Chief Executive Officer, Director

Yuval Cohen

Chief Financial Officer

Sean Moran

Chief Medical Officer

Dominic Smethurst

Independent Director

Anne Altmeyer